Cancer Diagnostics Firm VolitionRX is Seeking $1.5 MillionCancer Diagnostics Firm VolitionRX is Seeking $1.5 Million

Cancer diagnostics firm VolitionRx has raised $595,000 out of a total of $1.5 million,

June 14, 2013

1 Min Read
Cancer Diagnostics Firm VolitionRX is Seeking $1.5 Million

Cancer diagnostics firm VolitionRx is looking to raise $1.5 million, according to a regulatory filing. It has already raised $595,000.

The company is developing various blood-based epigenetic cancer diagnostic tests and the company hopes that these tests will advance cancer diagnosis of various types. Currently, the only blood test available to screen for cancer is prostate cancer screening, according to VolitionRx.

The Singapore-based firm with offices in Belgium aims to change that by introducing its NuQ tests that is based on its proprietary Nucleosomics technology that identifies and measures the nucleosome structures in the blood. The company trades over the counter bulletin boards.

Cameron Reynolds is the company's president and CEO.

-- By Arundhati Parmar, Senior Editor, MD+DI

Sign up for the QMED & MD+DI Daily newsletter.

You May Also Like